Eugia Pharma Specialities receives USFDA approval for Amphotericin B Liposome for Injection 50 mg

25 Nov 2022 , 01:35 AM

Aurobindo Pharma announced that its wholly owned subsidiary company Eugia Pharma Specialities has received a final approval from the US Food Drug Administration USFDA for hotericin B Liposome for Injection 50 mg hotericin B Liposome for Injection 50 mgvial Single-Dose Vial to be bioequivalent and therapeutically equivalent to the reference listed drug RLD AmBisome Liposome for Injection 50 mgvial of Astellas Pharma US Inc The product is expected to be launched by Q4 FY23 The approved product has an estimated market size of around US$ 145 million for the twelve months ending September 2022 according to IQVIA This is a partnership product from TTY Biopharm Company Limited and will be manufactured at their Taiwan facility and marketed by Eugia Pharma